$QBIO Q BioMed says new publication shows superior safety and efficacy of Uttroside-B versus FDA approved drug Sorafenib https://t.co/xC2U7q9wqf @QBioMed#QBIO
Q BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancer
https://t.co/4r1gsB6fJj
$QBIO
$QBIO Q BioMed says its strategy is paying off as it outlines its value proposition in multibillion-dollar markets https://t.co/3BmB2YN97j @QBioMed#QBIO
$QBIO Q BioMed announces publication of research supporting efficacy and development of its Uttroside-B chemotherapeutic to treat liver #Cancer https://t.co/kHHHoKDjCB @QBioMed#QBIO
Q BioMed announces publication of research showing augmented efficacy of its drug candidate Uttroside-B against liver cancer
https://t.co/OLQg6hwZLi
$QBIO
Strontium89 (Strontium Chloride Sr-89 Injection, USP) is the only approved radiotherapy currently available in the U.S. indicated for metastatic cancer bone pain palliation. $QBIO #Cancer